A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent.
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.
Johnson & Johnson’s first quarter results reflected a steady performance, with the company surpassing Wall Street’s revenue and adjusted profit expectations. Management credited the diversified portfolio across innovative medicine and MedTech as key to navigating industry challenges, particularly the loss of market exclusivity for STELARA, a major pharmaceutical product. CEO Joaquin Duato highlighted, “No other healthcare company has delivered growth through the first year of Lucin exclusivity for a multibillion-dollar product...and yet, that is exactly what we are doing.” The company’s ability to offset biosimilar competition with double-digit growth from eleven key brands and strong operational execution was a central theme of the quarter.
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Johnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.
